2. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) takes the No. 2 position as a surgical-robotics company working to transform the treatment of benign prostatic hyperplasia. Its AQUABEAM platform enables Aquablation therapy, using robotically controlled, heat-free waterjet technology to remove prostate tissue while helping physicians plan and execute procedures with greater precision.
Second-quarter 2026 revenue increased 19% to $94.5 million. U.S. revenue rose 20% to $83.4 million, international revenue increased 15% to $11.1 million, and U.S. system revenue climbed 32% to $29.1 million. U.S. handpiece and consumable revenue reached $48.4 million, increasing 12%, demonstrating the recurring-revenue opportunity created as hospitals purchase more systems and perform additional procedures.
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) remained unprofitable, reporting a quarterly net loss of approximately $26.9 million and an adjusted EBITDA loss of $11.3 million. Hospital capital budgets, competing treatments, operating expenses, and the need to convert system placements into higher procedure volumes remain major risks. However, its large addressable market, growing installed base, recurring consumable sales, and disruptive medical technology make PROCEPT BioRobotics Corporation (NASDAQ: PRCT) a compelling long-term growth candidate.
